We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

By LabMedica International staff writers
Posted on 28 Oct 2019
Cancer researchers developed a 29 gene–based weighted prognostic score for predicting event-free survival and overall survival of patients suffering from diffuse large B-cell lymphoma (DLBCL).

DLBCL is the most common type of non-Hodgkin lymphoma, an aggressive cancer that begins in certain immune system cells and can occur almost anywhere in the body. More...
This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age, although it can also occur in children and young adults in rare cases. An elevated level of circulating cell-free DNA (cfDNA) has been associated with tumor mass and poor prognosis in DLBCL, but the tumor-specific molecular alterations in cfDNA with prognostic significance have remained unclear.

To help clarify this issue, investigators at the University of Chicago Medical Center (IL, USA) studied the association between 5-hydroxymethylcytosines (5hmC), a mark of active demethylation and gene activation, in cfDNA from blood plasma and prognosis in newly diagnosed DLBCL patients.

The investigators emplyed the 5hmC-Seal, a highly sensitive chemical labeling–based sequencing technology, to profile genome-wide 5hmC in cfDNA from blood plasma of 48 patients with newly diagnosed DLBCL. This technology used the T4 bacteriophage beta-glucosyltransferase to transfer an engineered glucose moiety containing an azide group onto the hydroxyl group of 5-hmC. The azide group could be chemically modified with biotin for detection, affinity enrichment, and sequencing of 5-hmC–containing DNA fragments. The 5hmC-Seal technology was shown to be a robust profiling approach for enriching and quantifying 5hmC-modified DNA fragments with as little as one to two nanograms of cfDNA in less than five milliliters of plasma.

The investigators tested the hypothesis that 5hmC profiles in cfDNA at the time of diagnosis reflected the clinical characteristics of DLBCL and were associated with survival. Results obtained during the study enabled the development of a 29 gene–based weighted prognostic score for predicting event-free survival and overall survival.

“Our findings, if validated in a larger independent patient population, could impact the cure rate for DLBCL,” said first author Dr. Brian Chiu, associate professor of epidemiology at the University of Chicago Medical Center. “By identifying those patients who are at high-risk of treatment failure, we can see who may benefit from individualized clinical management or earlier treatment with novel or targeted therapies.”

The study was published in the October 8, 2019, online edition of the journal Blood Advances.

Related Links:
University of Chicago Medical Center


Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
Portable Electronic Pipette
Mini 96
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researcher Sudhaunsh Deshpande holding the molecularly imprinted polymer-based biosensor (Photo courtesy of University of Liverpool)

AI-Powered Blood Tests Enable Early Detection of Alzheimer’s Disease

Alzheimer’s disease, the most common form of dementia, affects more than 55 million people globally. Early diagnosis is critical for managing symptoms and slowing progression, yet current testing methods... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The tool enables scientists to track real-time fluctuations in T cell function with unprecedented speed and precision (Photo courtesy of Shutterstock)

Luminescent Probe Measures Immune Cell Activity in Real Time

The human immune system plays a vital role in defending against disease, but its activity must be precisely monitored to ensure effective treatment in cancer therapy, autoimmune disorders, and organ transplants.... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.